(HIT) Health In Tech Common - Ratings and Ratios
Insurance, Platform, SaaS, Software, Solutions, Healthcare, Technology
HIT EPS (Earnings per Share)
HIT Revenue
Description: HIT Health In Tech Common
Health In Tech, Inc. is an insurance technology platform company that offers a range of innovative solutions, including reference-based pricing, group insurance captives, and community health plans, targeting small businesses and medium-sized employers. Their eDIYBS platform is a web-based SaaS quoting platform that simplifies the process of quoting health insurance. Additionally, they provide a Health Intelligence (HI) card to streamline medical records and claims management, as well as the HI Performance Network, which offers a network of hospital facilities with Medicare-based reimbursement pricing.
To further analyze the companys performance, we can look at key performance indicators (KPIs) such as revenue growth, customer acquisition costs, and retention rates. Given the companys focus on insurance technology, its likely that their revenue growth is driven by the adoption of their SaaS platform and the number of employers using their services. A potential KPI to monitor is the companys gross margin, which could indicate the scalability of their business model. With a market capitalization of $322.79M USD, Health In Tech, Inc. has a significant presence in the Software - Application industry.
From a profitability perspective, the companys Return on Equity (RoE) of 10.48% suggests that they are generating returns for their shareholders, although this is a relatively modest figure. The Price-to-Earnings (P/E) ratio of 199.00 indicates that the stock may be overvalued, potentially due to high growth expectations. To better understand the companys valuation, it would be useful to examine their earnings per share (EPS) growth rate and compare it to industry peers.
To drive actionable insights, we need to focus on the companys operational metrics, such as the number of employers and employees using their platforms, revenue per user, and customer satisfaction ratings. By analyzing these metrics, we can gain a deeper understanding of Health In Tech, Inc.s growth prospects and potential areas for improvement.
Additional Sources for HIT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
HIT Stock Overview
Market Cap in USD | 323m |
Sector | Technology |
Industry | Software - Application |
GiC Sub-Industry | Insurance Brokers |
IPO / Inception | 2024-12-23 |
HIT Stock Ratings
Growth Rating | -37.8 |
Fundamental | 54.1 |
Dividend Rating | 0.0 |
Rel. Strength | -78.2 |
Analysts | - |
Fair Price Momentum | 0.99 USD |
Fair Price DCF | 0.38 USD |
HIT Dividends
Currently no dividends paidHIT Growth Ratios
Growth Correlation 3m | 40.6% |
Growth Correlation 12m | -62.5% |
Growth Correlation 5y | -62.5% |
CAGR 5y | -76.47% |
CAGR/Max DD 5y | -0.83 |
Sharpe Ratio 12m | 0.72 |
Alpha | -105.22 |
Beta | 2.462 |
Volatility | 134.54% |
Current Volume | 538.6k |
Average Volume 20d | 406.1k |
Stop Loss | 1.1 (-8.3%) |
As of July 19, 2025, the stock is trading at USD 1.20 with a total of 538,564 shares traded.
Over the past week, the price has changed by +8.11%, over one month by +104.26%, over three months by +75.18% and over the past year by -76.47%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Health In Tech Common (NASDAQ:HIT) is currently (July 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 54.12 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of HIT is around 0.99 USD . This means that HIT is currently overvalued and has a potential downside of -17.5%.
Health In Tech Common has no consensus analysts rating.
According to our own proprietary Forecast Model, HIT Health In Tech Common will be worth about 1.2 in July 2026. The stock is currently trading at 1.20. This means that the stock has a potential downside of -1.67%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 1.2 | -1.7% |